Purpose To provide an overview of the tuberculosis (TB) and multi-drug resistant tuberculosis (MDR-TB) in the WHO European Region and evolution of public health response with focus on extra-pulmonary tuberculosis and Pott's disease. Methods Authors reviewed regional strategic documents related to TB. The epidemiologic data were reviewed and analyzed.
Extra-pulmonary tuberculosis in the WHO European Region
In 2010, among the 388,875 notified TB cases in the WHO European Region, 65,783 (17 %) cases had extra-pulmonary TB [1] . This proportion of extra-pulmonary cases has remained relatively stable over the last 4 years. Pott's disease is reported together with other extra-pulmonary TB cases to the joint WHO/ECDC surveillance system and as a result the exact magnitude of the disease is unknown. Country reporting by disaggregated site of disease is good with most countries reporting\1 % of cases with unknown disease localization. Only Turkmenistan, Bosnia and Herzegovina and Denmark still need to improve their notification by disease localization; these countries reported 8.5 %, 11.4 %, and 18.1 % cases with unknown site of disease, respectively. On average, in the European Union/ European Economic Area (EU/EEA) countries, a higher proportion of extra-pulmonary localization of the disease among all TB cases was observed than in non-EU/EEA countries; 22 % versus 16 % (Fig. 3) . Five countries reported more than 40 % of extra-pulmonary TB cases: the United Kingdom (47 %), the Netherlands (45 %), Andorra (43 %), Norway and Malta (41 % each) [1] . The variances in the reporting of extra-pulmonary TB may result from different diagnostic practices across the region or epidemiological factors, such as immigration or the prevailing M. tuberculosis strains [2] .
Only for EU/EEA countries anti-TB drug resistance was recorded by site of disease. Among all 31,644 cases with drug susceptibility available in EU/EEA countries, 6,933 were from extra-pulmonary TB cases. The rate of MDR-TB among extra-pulmonary TB cases with drug susceptibility available was 2.3 % (n = 158). This rate was lower than the rate of 5.2 % MDR-TB among pulmonary TB cases (n = 1,289). The reasons for this need further investigation.
Because of the limited Regional surveillance reporting on data disaggregated by disease localization, further analysis on extra-pulmonary disease, e.g., by HIV status is currently not possible and treatment outcome for cases with this kind of disease is not available.
Development and implementation of the DOTS Strategy
In 1991, the World Health Assembly recommended that each National Tuberculosis Programme (NTP) work toward two objectives (the ''WHO targets'') by the year 2000: (1) to detect at least 70 % of all sputum smear positive cases, and (2) to treat at least 85 % of them successfully, by the introduction of an effective approach to TB control [3] which according to the ''World Development Report 1993'', is considered to be one of the most cost-effective health interventions [4] . In 1993, because of resurgence of TB globally, WHO took an unprecedented step and declared TB a global emergency. In 1994, after defining the nature and size of the global TB problem through expanded monitoring and surveillance, the International Union Against Tuberculosis and Lung Disease (The Union) and WHO promoted the technical and managerial approach suggested by Karel Styblo in the 1970s. In 1995, the strategy was packaged and branded as ''Directly Observed Treatment Shortcourse'' (DOTS).
The DOTS Strategy incorporating the fundamentals of TB control focused on a five-point policy package [5] 1. Government commitment to sustained TB control; 2. Sputum smear microscopy to detect the infectious cases; 3. Standardized and directly observed short-course chemotherapy; 4. Uninterrupted supply of medicines; 5. Supervision, Monitoring and Evaluation.
During the period of 1995-2005, the emphasis was on piloting and expanding the DOTS Strategy. DOTS was widely accepted and adopted as a package of essential TB control measures, depending on the peculiarities of certain countries and local circumstances [5, 6] .
As a combination of technical and managerial elements, DOTS proved to be effective making the infectious cases as non-infectious and breaking the cycle of transmission. The number of countries using DOTS expanded from only 10 in 1990 to more than 180 in 2005, covering more than 80 % of the world population [7] .
After the collapse of the Soviet Union and mainly due to disruption of health services, TB re-emerged in the Region. In response, WHO and other partners scaled up their support for implementation and expansion of DOTS [6] . In 2002, the WHO/Europe Regional Committee endorsed the ''DOTS expansion plan to Stop TB in the WHO European Region 2002-2006'' [8, 9] .
From DOTS to Stop TB Strategy
The DOTS Strategy has led to major progress in global TB control with successful treatment of nearly 20 million patients worldwide during 1995-2005 [8] . However, new challenges, such as the worsening of the HIV epidemic and rising of TB/HIV co-infection, emergence of drug-resistant strains TB and poor access of most vulnerable population, have proved that DOTS alone will not be sufficient for effective TB control [7, [9] [10] [11] .
In 2006, WHO developed a new comprehensive strategy for TB control that consists of six components, which builds on and goes beyond DOTS. This strategy addresses the spread of TB and HIV co-infections and MDR-TB [12] . Up to now this is a leading strategy for TB control worldwide, including in the European Region where the rates of M/XDR-TB are the highest in the world and HIV is spreading most rapidly [13] [14] [15] . The aim of the Stop TB Strategy is to dramatically reduce the global burden of TB, by halting the epidemic and reversing it by 2015, with the ultimate goal to eliminate TB as a public health problem by 2050. The aims, detailed objectives and targets of the strategy are summarized in Table 1 . The six components of the Stop TB Strategy include to (1) pursue high-quality DOTS expansion and enhancement; (2) address TB/HIV, MDR-TB, and the needs of poor and vulnerable populations; (3) contribute to health system strengthening based on primary health care; (4) engage all care providers; (5) empower people with TB, and communities through partnership; (6) enable and promote research. The implementation approaches of these components are listed in Table 2 .
DOTS as a five-point package remains the first component and foundation of the Stop TB Strategy. The other components of the Strategy highlight the need to address the challenge of drug-resistant TB and the co-epidemics of TB and HIV, the importance of engaging all care providers in TB care and control and of contributing to strengthening health systems, the role of communities and people with TB, and the fundamental role of research and development for new diagnostics, new drugs and new vaccines.
Implementation of the Stop TB Strategy and future TB control in the WHO European Region
Evidence-based data suggest that improved diagnosis and treatment based on the Stop TB Strategy have already saved millions of lives globally [16] . The decline of TB incidence is \1 % per year and the long-term elimination target, to reduce incidence to less than one case per million by 2050, will not be reached with existing technologies and approaches [10, 11] . Trend analysis of the MDG targets in 2010 showed that estimated prevalence in the European Region has been declining, but not enough to be able to [18, 19] .
The Forum and the Declaration in particular renewed commitments to take actions to control TB in the European Region highlighting that: (1) TB, and MDR-TB in particular, is a health security threat; (2) Strengthening political and financial commitment is vital to reach the MDGs and (3) to establish adequate fora and mechanisms to assess progress at regional level [18] .
It is known that TB is a social disease and it is seen frequently in stigmatized and vulnerable groups such as the poor, migrants, drug abusers, prisoners. Activities are going on currently to reach these groups, addressing social determinants, ethical values and human rights in collaboration with other programmes within WHO as well as national and international partners [10, 11] .
Action Plan to prevent and combat M/XDR-TB in WHO European Region 2011-2015
M/XDR-TB is a man-made phenomenon that emerges as a result of inadequate treatment of tuberculosis and/or poor airborne infection control in health care facilities and congregate settings. The spread of M/XDR TB is also an indication to low adherence to evidence-based TB control practices [13-15, 20, 21] .
WHO Regional Office for Europe, in collaboration with technical agencies, Member States, civil society organizations and communities, developed a Consolidated Action Plan to Prevent and Combat M/XDR-TB in WHO European Region 2011-2015. The Consolidated Action plan and its accompanying resolution EUR/RC61/R7 were fully endorsed at the sixty-first session of the WHO Regional Committee for Europe in Baku, Azerbaijan in September 2011 [22] . The plan emphasizes on strengthening the quality of implementation of the Stop TB Strategy, in particular the essential elements of TB control, such as early detection and notification of all TB cases as well as supervised treatment avoiding the misuse of anti-TB drugs [22] .
The plan calls for accelerated action, working in close partnership with member states and all partners, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria and the Stop TB Partnership. The goal of the plan is to contain the spread of drug-resistant TB by achieving universal access to prevention, diagnosis and treatment of M/XDR-TB in all member states in the WHO European Region by 2015. The targets of the plan are to diagnose at least 85 % of all estimated MDR-TB patients, treat successfully at least 75 % of all patients notified as having MDR-TB and to decrease by 20 % points the proportion of MDR-TB among previously treated patients [21] .
The Consolidated Action plan to prevent and combat M/XDR-TB comprises six strategic directions and seven areas of intervention. The strategic directions are crosscutting and are designed to safeguard the values of the Health 2020 strategy. These include: (1) identifying and addressing determinants and underlying risk factors contributing to the emergence and spread of drug-resistant TB; (2) strengthening the health system response in providing accessible, affordable and acceptable services using patient-centered approaches; (3) working in national, regional and international partnerships on TB prevention, control and care; (4) fostering regional and international collaboration for development of new diagnostic tools, medicines and vaccines against TB; (5) promoting rational use of existing resources, identifying gaps and mobilizing additional resources to fill the gaps; (6) monitoring the trends of M/XDR-TB in the Region and measuring the impact of interventions.
The areas of intervention are in line with the Global Plan to Stop TB 2011-2015 and include the same targets as set by the Global Plan and World Health Assembly resolution WHA62.15, namely to provide universal access to diagnosis and treatment of MDR-TB: (1) prevent the development of M/XDR-TB cases; (2) scale up access to testing for resistance to first-and second-line anti-TB drugs and to HIV testing and counseling among TB patients; (3) scale up access to effective treatment of drug-resistant TB; (4) scale up TB infection control; (5) strengthen surveillance, including recording and reporting, of drug-resistant TB; (6) expand country capacity to scale up the management of drug-resistant TB, including advocacy, partnership and policy guidance; (7) address the needs of special populations.
The action plan clearly defines milestones and a detailed set of recommended activities. Furthermore, a monitoring framework was developed to track progress toward milestones and the eventual achievement of objectives.
To address the lack of international consensus on the role of surgery in pulmonary and extrapulmonary TB including tuberculosis spondylitis, the plan foresees that the WHO Regional Office in collaboration with the Member States and other partners develop a set of evidence-based criteria for surgery for M/XDR-TB patients by the end of 2012.
If the Plan is implemented, 225,000 MDR-TB patients will be detected and 127,000 of them will be successfully treated (Fig. 4) . As a result of successful implementation of the Plan, 250,000 MDR-TB and 13,000 XDR-TB cases would be averted and 120,000 lives will be saved. The direct economic gain in lives saved by the Plan amounts to US$ 5 billion over the 5 years. In addition, US$ 7 billion will be saved directly on costs for detection and care of the M/XDR-TB cases averted, which would have arisen and needed treatment in the absence of improved TB control provisions of the plan. Its implementation will also have an impact on preventing transmission, and thus averting many more MDR-TB cases beyond 2015 that are as yet undetermined, but will go far beyond this number.
Conclusion
TB is still causing a considerable health burden in the WHO European Region, with increasing MDR-TB rates. There is a need to improve surveillance and/or conduct surveys to get a better understanding on the extent of Pott's disease and the reasons for the wide variation of the proportion of extrapulmonary TB among all TB cases across the Region. Countries need to urgently scale up the implementation of the Stop TB Strategy, ensuring early diagnosis and proper treatment, strengthening health-system policies, establishment of links with the broad economic and health reforms, including addressing social determinants of TB, and promotion of research efforts, including the development of new diagnostics, anti-TB drugs and vaccines.
Adequate interventions addressing drug-resistant TB require proper national planning and effective implementation of comprehensive approaches with the support from national and international partners. Further research on optimal treatment and care for Pott's disease is needed. Fig. 4 Expected achievements from implementation of the Consolidated Action Plan to present and combat M/XDR-TB in the WHO European Region, 2011-2015 [21] 
